Report Publication Announcement • Dec 11, 2014
Report Publication Announcement
Open in ViewerOpens in native device viewer
PARIS, December 11, 2014 – Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, announced today its schedule for the publication of financial information for 2014.
| Event | Date * |
|---|---|
| 2014 Full-Year Sales | January 7, 2015 |
| 2014 Full-Year Results and 2015 First-Quarter Sales | April 14, 2015 |
| Annual General Meeting | June 16, 2015 |
| 2015 First-Half Sales | July 15, 2015 |
| 2015 First-Half Results | September 9, 2015 |
| 2015 Third-Quarter Sales | October 15, 2015 |
* Subject to modification. Press releases are published after market closes.
Mauna Kea Technologies is a global medical device company focused on leading innovation in endomicroscopy and optical biopsy. The company designs, develops and markets innovative tools to visualize and detect cell abnormalities in real time during standard gastrointestinal and pulmonary endoscopy procedures. The company's flagship product, Cellvizio®, a probe needlebased Confocal Laser Endomicroscopy (pCLE/nCLE) system, provides physicians and researchers with high-resolution cellular imaging of internal tissues. Large-scale, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians to more accurately detect early forms of diseases and make immediate treatment decisions. Designed to help physicians in their diagnoses, provide patients with better treatment and reduce hospital costs, the Cellvizio system can be used with virtually any endoscope. Cellvizio has 510(k) clearance from the United States Food and Drug Administration and CE Marking in the European Union for use in the gastrointestinal tract and the urinary and respiratory systems, for endoscopic exploration of the biliary and pancreatic ducts and for fine-needle aspiration procedures. Cellvizio has also obtained SFDA regulatory approval in China and MHLW approval in Japan.
For further information on Mauna Kea Technologies, visit www.maunakeatech.com
Madis Phileo Press Relations
Marina Rosoff Tel: +33 (0)6 71 58 00 34 [email protected] NewCap
Europe - Investor Relations Florent Alba / Pierre Laurent Tel.: +33 (0)1 44 71 94 94 [email protected]
Westwicke Partners United States - Investor Relations Mark Klausner Tel.: +(443) 213-0500 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.